Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.

We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM vaccine that recently received emergency use authorization by the Drugs Controller General ofIndia. We compared the immune response of mice vaccinated with RBD/alum to mice vaccinated with RBD/alum + CpG. We also evaluated mice immunized with RBD/alum + CpG and boosted with RBD/alum. Mice were immunized twice intramuscularly at a 21-day interval. Compared to two doses of the /alum formulation, the RBD/alum + CpG vaccine induced a stronger and more balanced Th1/Th2 cellular immune response, with high levels of neutralizing antibodies against the original Wuhan isolate of SARS-CoV-2 as well as the B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 and (Delta) variants. Neutralizing antibody titers against the B.1.1.529 (BA.1, Omicron) variant exceeded those in human convalescent plasma after Wuhan infection but were lower than against the other variants. Interestingly, the second dose did not benefit from the addition of CpG, possibly allowing dose-sparing of the adjuvant in the future. The data reported here reinforces that the RBD/alum + CpG vaccine formulation is suitable for inducing broadly neutralizing antibodies against SARS-CoV-2, including variants of concern.

Complicaciones endocrinológicas de psicofármacos en psiquiatría infantil / Endocrinological complications of psychoactive drugs in childhood psychiatry

El uso de psicofármacos en el ejercicio de la psiquiatría infantil es cada vez mayor en los últimos años. Su correcto uso requiere que el psiquiatra desarrolle a partir del diagnóstico, un tratamiento que incluya una monitorización adecuada en el caso de uso de psicofármacos, ya que esto nos permitirá tener los mejores resultados con menores efectos adversos, como también la mejor adhesión al tratamiento que se haya propuesto (1). En esta revisión encontraremos varios fármacos de uso común en el ejercicio de la profesión, asociado a efectos adversos endocrinológicos que se han descrito en la literatura, seguido de recomendaciones de manejo y seguimiento.

The use of psychotropic drugs in child psychiatry has increased in recent years. Its correct use requires that the psychiatrist develops from starting point of a diagnosis, a treatment that includes an appropriate monitoring of the use of psychotropic drug, since this will allow the patient to have the best results with fewest adverse effects, as well as the better adherence to the treatment (1). In this review we will discuss several drugs commonly used in the practice of the profession, associated with adverse endocrine effects that have been described in the literature, followed by recommendations for management and monitoring.